Novel drug interactions at D(2) dopamine receptors: modulation of [3H]quinpirole binding by monoamine oxidase inhibitors.
D(2) dopamine receptors are the principal target of drugs used to treat schizophrenia and Parkinson's disease. Recent findings suggest novel drug interactions at D(2) receptors, specifically interactions of monoamine oxidase inhibitors (MAOIs) at a novel binding site that modulates the binding of [3H]quinpirole to the D(2) receptor. That MAOIs inhibit [3H]quinpirole binding challenges the traditional understanding of ligand interactions at dopamine receptors and may shed light on the mechanism of behavioral sensitization to psychostimulants and the pharmacology and toxicity of MAOIs.
Levant
Beth
B
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City 66160-7417, USA. blevant@kumc.edu
D000818:Animals; D018491:Dopamine Agonists / Q000378:metabolism* / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000378:metabolism* / Q000494:pharmacology; D019257:Quinpirole / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000187:drug effects* / Q000378:metabolism; D014316:Tritium
D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D017448:Receptors, Dopamine D2; D014316:Tritium; D019257:Quinpirole